Clinical Trial Update: Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy of Symbicort versus its monocomponents in asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED